Roche Amends Licensing Agreement With Chugai Pharma

In Japan, Chugais research institutes are collaborating in Gotemba and Kamakura to develop new pharmaceutical products and Ukima laboratories looking for technological development for industrial production. Overseas, Singapore-based Chugai Pharmabody Research is researching the development of new antibody drugs using innovative engineering technologies for chugais proprietary antibodies. Chugai Pharma USA and Chugai Pharma Europe are active in clinical development in the United States and Europe. Since the strategic alliance, Roche`s product licensing has expanded our product line and development pipeline. Chugai has won the No. 1 share of the oncology market in Japan.1 SA237 was invented by Chugai to block the activity of the IL-6 receptor and successfully applies Chugais proprietary antibody recycling technology. This design allows the antibody to attach it to the target antigen several times to develop antibody activity. With its design, SA237 should present clinical benefits with small injection volumes and long intervals between injections. Two multinational Phase III studies in patients with neuromyelitis optica, an autoimmune disease of the central nervous system characterized by severe inflammation of the optic nerve and spinal cord, are currently being conducted by Chugai in more than ten countries, including the United States, Europe and Asia. Roche owns 59.9% of Chugai`s outstanding shares on the basis of the Strategic Alliance Agreement. Unlike typical mergers, the name of the company and the ceo of Chugai have not been changed and the agreement has allowed Chugai to maintain its management autonomy. In addition, the two sides agreed to cooperate to keep Chugai, a publicly traded company, on the first section of the Tokyo Stock Exchange. The purpose of the licensing agreement is to use Chugais proprietary technologies to develop new antibody therapy drugs.

This class of active substances has potential in a variety of diseases and diseases such as Crohn`s disease, breast cancer, arthritis, transplant rejection, leukemia, asthma and psoriasis. Chugai specifically named its proprietary antibody technologies in the Roche license. Since the beginning of the strategic alliance with Roche, Chugai`s products have also been successfully recognized, including the names of revolutionary therapies by the U.S. Food and Drug Administration (FDA). For MediaChugai Pharmaceutical Co., Ltd. Media Relations Group, Koki HaradaTel: `81-3-3273-0881E-mail: pr@chugai-pharm.co.jp For US MediaChugai Pharma USA Inc.Casey AstringerTel: `1-908-516-13 50E-Mail: pr@chugai-pharm.com For European MediaChugai Pharma France SASNathalie LeroyTel: `33-1-56-37-05-21E-Mail: pr@chugai.eu`For Taiwanese mediaChugai Pharma Taiwan Ltd.Susan Chou, Osamu KagawaTel: `886-2-2715-2000E-Mail: pr@chugai.com.tw-For InvestorsChugai Pharmaceutical Co., Ltd.Investor Relations Group, Corporate Communications Dept.,Toshiya SasaiTel: `81-3-3273-0554E-mail: ir@chugai-pharm.co.jp Chugais` strategic alliance with Roche began in October 2002.